Reactive Oxygen Species-Enhanced Low-Dose Chemo-Photodynamic Therapy for Gastric Cancer
Reactive Oxygen Species-Enhanced Low-Dose Chemo-Photodynamic Therapy for Gastric Cancer
复制标题
活性氧增强低剂量化疗光动力疗法治疗胃癌
DOI：
10.1166/jbn.2022.3486
复制
发表时间：
2022-12
影响因子：
2.9
通讯作者：
Jing Xin
中科院分区：
文献类型：
--
作者：
Jing Wang;Wenbo Li;Xiaofeng Liu;Jing Xin
光敏剂可以基于能量或电子转移过程与氧或底物反应，以产生自由基、单线态氧（SOG）或其他活性氧物质（ROS）。SOG可以破坏细胞成分并最终导致细胞死亡。然而，SOG代
需要足够的氧气。因此，在缺氧的肿瘤组织中，包括胃癌，通过SOG的光动力疗法（PDT）的效果可能会降低。在这里，我们合成了一种纳米级的阳离子脂质体，它与光敏剂和低剂量化疗药物相关，
从而提高ROS介导的PDT效应，降低化疗引起的耐药和副作用的风险。采用阳离子脂质体作为药物载体，提高了药物的释放效率，延长了药物循环时间，实现了药物的同时释放，
光敏剂和化疗药物。采用与ROS相关的低剂量化疗药物，以增加线粒体膜的通透性，诱导高水平的光敏剂进入细胞，从而产生毒性ROS。一般
ROS介导的增强效应可迅速诱导细胞凋亡。这种整合的纳米级阳离子脂质体系统是一种潜在的胃癌治疗药物，并且是基于增强的ROS介导的协同治疗。
A photosensitizer can react with oxygen or a substrate based on energy or electron transfer processes in order to generate free radicals, singlet oxygen (SOG), or other reactive oxygen species (ROS). SOG can damage cellular components and eventually cause cell death. However, SOG generation
requires sufficient oxygen. Therefore, the effect of photodynamic therapy (PDT) via SOG may be decreased in oxygen-deficient tumor tissues, including gastric cancer. Here, we synthesized a nanosized cationic liposome integrated with a photosensitizer and low-dose chemotherapeutic drug related
to ROS to improve the ROS-mediated PDT effect and lower the risk of drug resistance and side effects induced by chemotherapy. The cationic liposome was used as a drug carrier to increase the efficiency of drug delivery, prolong drug circulation time, and achieve the simultaneous delivery of
the photosensitizer and chemotherapeutic drug. The low-dose chemotherapeutic agent related to ROS was adopted for increasing the permeability of the mitochondrial membrane and inducing the entry of high levels of the photosensitizer into the cell so as to generate toxic ROS. Generally, the
ROS-mediated enhanced effect could quickly induce long-lasting apoptosis. This integrated nanosized cationic liposome system is a potential agent for gastric cancer therapy and is based on enhanced ROS-mediated synergistic therapy.
登录
查看更多内容
影响因子：
12.4
作者：
Yue C;Zhang C;Alfranca G;Yang Y;Jiang X;Yang Y;Pan F;de la Fuente JM;Cui D
通讯作者：
Cui D
影响因子：
12.4
作者：
Zhang, Min;Zhao, Yifan;Ma, He;Sun, Yusong;Cao, Jie
通讯作者：
Cao, Jie
影响因子：
26.6
作者：
Yu R;Zhang H;Guo B
通讯作者：
Guo B
影响因子：
5.6
作者：
Costa-Júnior JM;Ferreira SM;Kurauti MA;Bernstein DL;Ruano EG;Kameswaran V;Schug J;Freitas-Dias R;Zoppi CC;Boschero AC;Oliveira CAM;Santos GJ;Carneiro EM;Kaestner KH
通讯作者：
Kaestner KH
影响因子：
10.2
作者：
Nosrati H;Aramideh Khouy R;Nosrati A;Khodaei M;Banitalebi-Dehkordi M;Ashrafi-Dehkordi K;Sanami S;Alizadeh Z
通讯作者：
Alizadeh Z